Ann: Half Yearly Report and Accounts, page-9

What I found was interesting was that alexiflame sales seem to be being held up by regulatory approval delays, is that anyone else's take on that! Nice to see cost of sales and revenue topping in the right direction. And it would seem Pegasus sales although taking longer to ramp up are heading in the right direction. I also liked the summary of market penetration and what could be availiable. Finally, I like that they have recognised how difficult penitrating an existing market is and that they are being proactive in figuring out the metrics to support their product,
Although I'd like more money in the till this is the most realistic report yet published, I think the next 4 c should be a positive and from there we may finally get some traction upwards. I might be in for some more around here based on this report.